CD44 Splice Variants as Potential Players in Alzheimer's Disease Pathology

Area of Science:

• Neuroscience
• Molecular Biology
• Immunology

Background:

• Alzheimer's disease (AD) is a neurodegenerative disorder marked by amyloid-β plaques, neurofibrillary tangles, and neuroinflammation.
• CD44, an inflammation-related gene, encodes cell surface glycoproteins involved in inflammation and neuronal injury.

Purpose of the Study:

• To investigate the expression patterns of CD44 standard (CD44S) and its splice variants in Alzheimer's disease (AD) hippocampal samples.
• To determine the role of CD44 splice variants in AD pathogenesis and neuronal cell death.

Main Methods:

• Analysis of CD44S, CD44V3, CD44V6, and CD44V10 expression in postmortem hippocampal tissues from AD patients and controls.
• Immunohistochemistry to localize CD44 variants in human hippocampal sections.
• In vitro studies using neuroblastoma cells and primary neurons treated with amyloid-β (Aβ) peptide.
• Loss-of-function studies using CD44V10-specific siRNA and antibody.

Main Results:

• Expression of CD44S, CD44V3, CD44V6, and CD44V10 was significantly higher in AD patients compared to controls.
• CD44S localized to neuritic plaques and astrocytes, while CD44V3, CD44V6, and CD44V10 were primarily neuronal.
• Aβ peptide induced CD44V6 and CD44V10 expression in neuronal cells.
• CD44V10 inhibition (siRNA or antibody) protected neuronal cells from Aβ-induced toxicity.

Conclusions:

• Specific CD44 splice variants, particularly CD44V10, are upregulated in Alzheimer's disease and contribute to Aβ-induced neuronal cell death.
• CD44V10 plays a causal role in AD pathogenesis.
• Targeting CD44V10 presents a potential neuroprotective therapeutic strategy for Alzheimer's disease.